The resemblance to CML patients in blast phase (BP) suggests that the emergence of resistance to TKIs is also promoted in a large proportion of patients by mutations in the kinase domain (KD) of BCR::ABL1. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.